please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . march 2015 learn how and when to remove this template message exelixis type public company traded as nasdaq exel industry biotechnology founded 1994 headquarters south san francisco california united states key people michael morrissey president research and development frank karbe cfo gisela m. schwab executive vice president and chief medical officer pamela a. simonton executive vice president and general counsel peter lamb senior vice president discovery research and chief scientific officer lupe m. rivera senior vice president operations website www.exelixis.com exelixis is a genomics based drug discovery company located in south san francisco ca . and the producer of cometriq a treatment approved by the u.s. food and drug administration fda for medullary thyroid cancer with clinical activity in several other types of metastatic cancer . it works on the development of anti cancer therapies . exelixis has several compounds in various stages of fda approval including xl147 that targets phosphoinositide 3 kinase pi3k ; and xl765 which targets pi3k and mtor kinases in the pi3k signaling pathway . xl880 foretinib the company also has various compounds in phase 1 clinical trials including xl518 or gdc0973 a small molecule inhibitor of the mek . co developed with roche . xl228 which targets insulin like growth factor type 1 receptor an rtk in a range of human tumors ; xl139 that targets hedgehog ; xl413 a small molecule inhibitor of the serine threonine kinase cdc7 ; xl888 a synthetic inhibitor of hsp90 a chaperone protein that promotes the activity and stability of a range of regulatory proteins including kinases . 1 its lead compound xl184 has been approved for treatment of medullary thyroid cancer and is currently in a number of clinical trials for prostate ovarian brain melanoma breast non small cell lung hepatocellular kidney . during its trial for the treatment of medullary thyroid cancer xl184 was designated orphan drug status by the fda and given the generic name cabozantinib . cabozantinib is an inhibitor of the tyrosine kinases met and vegfr2 and has been shown to abrogate tumor growth metastasis and angiogenesis . see also edit act biotech inc references edit http seekingalpha.com article 270085 exelixis looming cancer conference a favorable swing trade opportunity external links edit wikimedia commons has media related to exelixis . official website this article about a medical pharmaceutical or biotechnological corporation or company is a stub . you can help wikipedia by expanding it . v t e retrieved from https en.wikipedia.org w index.php title exelixis & oldid 734091878 categories companies listed on nasdaqcompanies in the nasdaq biotechnology indexbiotechnology companies of the united statesmedical company stubshidden categories articles needing additional references from march 2015all articles needing additional referencespages using infobox company with unsupported parameterscommons category with page title same as on wikidataall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version in other projects wikimedia commons languages add links this page was last modified on 12 august 2016 at 02 48 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view